PAR. SP, page-275

I agree. PAR needs to start approaching competitors to Novartis who have an interest in the OA market and sign a partnership deal to help fund the P3 trials. Unfortunately PAR can no longer go it alone given the current situation and may be forced to give up a higher proportion of the value of the iPPS asset. It shouldn't be difficult for PAR to strike a deal for the US OA market perhaps for a 150 million upfront and double digit royalties, whereas PAR gets the rights to the rest of the world. While it's admirable that PAR wanted to go it alone, I think that is no longer an option.